BFCH Strengthens Portfolio with Acquisition of EVERMIND™ Beverage, Aiming for Cognitive Health Market Leadership
BitFrontier Capital Holdings, Inc. (BFCH) has signed a binding LOI to acquire EVERMIND™, a science-backed cognitive health beverage platform, marking a strategic move to bolster its balance sheet and position for future growth in the wellness sector.
BitFrontier Capital Holdings, Inc. (OTC: BFCH), operating as EVERMIND Holdings, Inc., has taken a significant step towards expanding its footprint in the cognitive health market by signing a binding Letter of Intent (LOI) to acquire ERApeutics, LLC, the developer of the EVERMIND™ beverage platform. This acquisition, valued at $4,000,000 through the issuance of 400,000,000 restricted common shares at $0.01 per share, is poised to enhance BFCH's balance sheet and support its OTCQB uplisting strategy.
EVERMIND™ stands out in the functional beverage space as a physician-formulated, plant-based protein shake designed to support cognitive health. With its shelf-stable, science-supported formulation, the brand is ready for commercialization, offering both short- and long-term brain health benefits. The acquisition includes six proprietary nootropic and adaptogenic formulations, an R&D pipeline, academic research, and registered trademarks, alongside a fully integrated e-commerce platform accessible at https://thinkevermind.com.
Dr. Jordan Balencic, CEO of BFCH, highlighted the strategic importance of this acquisition, comparing EVERMIND™'s potential impact on cognitive health to Celsius's influence on metabolism. The deal not only adds IP-backed assets to BFCH's portfolio but also aligns with the company's broader strategy to eliminate toxic debt and prepare for institutional capital engagement. With the functional beverage market attracting significant investment, as seen in recent deals by Keurig Dr Pepper and Coca-Cola, EVERMIND™ positions BFCH to capitalize on the growing demand for wellness-oriented products.
The transaction, expected to close within 60 to 90 days, will see EVERMIND™ operating as a wholly owned subsidiary of EVERMIND Labs, with potential for future spin-offs. This move underscores BFCH's commitment to building a diversified wellness and performance platform, leveraging acquisitions like EVERMIND™ to drive growth and shareholder value. For more details on the acquisition and BFCH's strategic direction, investors can view the investor pitch at https://evermindholdings.com/evermind-beverage/.